Alnylam Pharmaceuticalsvs.Amgen
ALNY vs AMGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 7.3× larger than Alnylam Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.2 vs 37.2); year to date, Amgen leads (+26.2% vs −43.5%).
Side by side
| ALNY | AMGN | |
|---|---|---|
| Market cap | $30B | $220B |
| Price | $232.68 | $414.87 |
| Today | +3.6% | +1.8% |
| Return YTD | −43.5% | +26.2% |
| Return 1Y | −50.2% | +39.8% |
| Since June 26, 2026 | −20.1% | +15.8% |
| P/E | 37.2 | 25.2 |
| P/S | 6.3 | 5.8 |
| P/B | 22.2 | 18.8 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →More ALNY & AMGN comparisons
Other head-to-heads in the Biotech & innovation segment.